Correction

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model (Jun, 10.1038/s41386-018-0150-5, 2022)

NEUROPSYCHOPHARMACOLOGY (2022)

Volume 47, Issue 9, Pages 1733-1733

DOI: 10.1038/s41386-022-01345-x

Click your name to claim this paper and add it to your profile.